Description: OncoSec Medical Incorporated, a hybrid device and gene therapy biotechnology company, designs, develops, and commercializes medical approaches principally immunotherapy for the treatment of solid tumors in the United States. Its clinical programs include three Phase II clinical trials to assess the ImmunoPulse technology in patients with melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma. It has a collaboration agreement with Heat Biologics, Inc. to evaluate the combination of immunotherapy platforms. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated is headquartered in San Diego, California.
Home Page: oncosec.com
ONCS Technical Analysis
24 North Main Street
Pennington,
NJ
08534
United States
Phone:
855 662 6732
Officers
| Name | Title |
|---|---|
| Dr. Robert H. Arch Ph.D. | Pres, CEO & Non-Independent Director |
| Mr. George Chi C.F.A., CPA | CFO, Exec. VP of Fin., Sec. &Treasurer |
| Mr. Robert J. DelAversano CPA | VP of Fin. and Principal Accounting Officer & Controller |
| Dr. Kim Jaffe Ph.D. | Assistant VP of Bus. Devel. & Operations |
| Mr. Tu Diep M.Sc. | Sr. VP & Head of Operations |
| Dr. Sandra Aung Ph.D. | Sr. VP & Chief Clinical Devel. Officer |
| Dr. Mai Hope Le M.D. | Consultant |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 8.6655 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7817 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2011-03-31 |
| Fiscal Year End: | July |
| Full Time Employees: | 40 |